Amgen’s Aimovig (erenumab-aooe) Receives FDA’s Approval for Prevention of Migraine in Adults

 Amgen’s Aimovig (erenumab-aooe) Receives FDA’s Approval for Prevention of Migraine in Adults

Amgen Reports In-Favor Uphold of its Two Patents for Repatha from Delaware Jury

Shots:

  • The approval is based on P-IIIb LIBERTY (NCT03096834) study results assessing Aimovig (140mg) vs PBO for duration of 12 weeks
  • The study resulted in 50% reduction of monthly migraine days sustained up to 15 months with the use of acute migraine drugs
  • Aimovig (erenumab-aooe) is a novel drug used for targeting Calcitonin Gene-Related Peptide Receptor (CGRP-R), with its awaited EMA approval

Click here to read full press release/ article | Ref: Amgen | Image: Axios

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post